Rashmi Chugh

TL;DR: Five new LBD-localized ESR1 mutations identified here were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro, suggesting that activating mutations in E SR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.

TL;DR: The results show that integrative sequence analysis provides a clinically relevant, multi-dimensional view of the complex molecular landscape and microenvironment of metastatic cancers.

TL;DR: Patients who relapse locally have a poor prognosis but both radiation and surgery can be used as salvage therapy, and subtotal resection can result in a stable or improved status in as many as 50% of patients who relapse after primary therapy.

TL;DR: Talazoparib as discussed by the authors showed single-agent antitumor activity and was well tolerated in patients at the recommended dose of 1.0 mg/day, with an elimination half-life of 50 hours.

TL;DR: R1507 was a well-tolerated agent that had meaningful and durable benefit in a subgroup of patients with ESFT and the identification of markers that are predictive of a benefit is necessary to fully capitalize on this approach.